职称：讲师
学历：博士
E-mail：zhangzijian@hbut.edu.cn
研究方向：肿瘤免疫与细胞治疗
个人简介：
湖北工业大学 讲师，主要研究方向为肿瘤免疫和CAR-T细胞治疗。以第一或通讯作者（含共同）在Nature Cancer, Nature Immunology, Cell research, Molecular Therapy, Journal of Hemato & Oncology, Acta Pharmacologica Sinica，Clinical and Translational Medicine发表多篇研究成果，近三年主持省级科研项目2项，授权专利4项。
教育及工作经历：
2025.10-至今 湖北工业大学 生命科学与健康工程学院 讲师
2023.09-2025.09 海南大学 药学院 博士后
2017.09-2023.06武汉科技大学 生命科学与健康学院 硕士+博士
2012.09-2017.06郑州大学 公共卫生学院 学士
近三年主要获奖：
1. 第八届中国国际“互联网+”大学生创新创业大赛 国家级铜奖
近年完成的主要论文(#共同第一作者, *通讯作者)：
1. Zijian Zhang，Qifang Wu，Anqi Ren，Qian Chen，Jiangzhou Shi，Jiapeng Li，Xiyu Liu，Zhijie Zhang，Yuzhe Tang，Yuan Zhao，Ningning Yao，Xiaoyu Zhang，Changpeng Liu，Ge Dong，Jiaxuan Zhao，Meijun Xu，Yunqiang Yue，Jia Hu，Fan Sun，Yu Liu，Qilin Ao，Fuling Zhou，Hong Wu，Tongcun Zhang*, Haichuan Zhu*. ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming. Acta Pharmacologica Sinica. 2023;44(11):2282-2295（IF=8.4).
2. Yishuang Sun#, Zijian Zhang#, Haiou Li#, Xia Bu#, Li Chen#, Xiyong Wang, Lijun，Kong, Panpan Dai, Wenjing Song, Xiangling Xiao, Jie Shi, Bolin Xiang, Chuan He. Yingmeng Yao, Wenjun Xiong, Haisheng Yu, Congqing Jiang, Hudan Liu, Sufang Tian, Guoliang Qing, Zhiyong Yang, Wenyi Weis*, Gordon J. Freeman*, Haichuan Zhu*, Jinfang Zhang*. Destruction of VISTA by TRlM25 ablation in T cells potentiates cancer immunotherapy. Cell research. 2025 Nov 13. doi: 10.1038/s41422-025-01186-5. (IF=25.9).
3. Jiangzhou Shi#, Zijian Zhang#, Hong Cen#, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin, Kunyu Yang, Tongcun Zhang*, Haichuan Zhu*. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of Hematology & Oncology. 2021 Oct 9;14(1):162 (IF=29.9).
4. Jie Shi#, Zijian Zhang#, Hsin-Yi Chen#, Yingmeng Yao, Shanwen Ke, Kechun Yu, Jiangzhou Shi, Xiangling Xiao, Chuan He, Bolin Xiang, Yishuang Sun, Minling Gao, Xixin Xing, Haisheng Yu, Xiyong Wang, Wei-Chien Yuan, Bugi Ratno Budiarto, Shih-Yu Chen, Tongcun Zhang, Yu-Ru Lee*, Haichuan Zhu*, Jinfang Zhang*. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR T cell therapy. Molecular Therapy, 2025 Mar 5;33(3):1073-1090.（IF=12.1）.
5. Bolin Xiang#, Meiling Zhang#, Kai Li#, Zijian Zhang#, Yutong Liu#, Minling Gao, Xiangling Xiao, Yishuang Sun, Chuan He, Jie Shi, HongZeng Fan, Xixin Xing, Gaoshan Xu, Yingmeng Yao, Gang Chen*, Haichuan Zhu*, Chengqi Yi*, Jinfang Zhang*, The epitranscriptional factor PClF1 orchestrates CD8+T cell ferroptosis and activation to govern anti-tumor immunity. Nature Immunology. 2025 Feb;26(2):252-264（IF=27.8）.
6. Jie Cheng#, Yifeng Xiao#, Ting Peng#, Zijian Zhang#, You Qin#, Yuqian Wang, Jiangzhou Shi, Jinxin Yan, Zhijun He, Jianwei Wang, Cheng Li*, Haichuan Zhu*, and Peng Jiang1*. ETV7 limits the antiviral and anti-tumor efficacy of CD8+ T cells by diverting their fate towards exhaustion. Nature Cancer. 2025 Feb;6(2):338-356（IF=23.5）.
7. Nuo Xu#, Zhaoya Gao#, Deyan Wu#, Hangyu Chen#, Zijian Zhang#, Lei Zhang, Yuchen Wang, Xuyang Lu, Xu Yao, Xuelan Liu, Yi-you Huang, Meiying Qiu, Sen Wang, Jinqiang Liang, Can Mao, Feng Zhang, Huimin Xu, Yujiao Wang, Xian Li, Zhexin Chen, Dandan Huang, Jingyi Shi, Wensheng Huang, Fuming Lei, Zeruo Yang, Long Chen, Chuan He, Haichuan Zhu*, Haibin Luo*, Jin Gu*, and Jian Lin*.5-hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target, Clinical and tranlational medision, 2025 Feb;15(2):e70189. (IF=7.9).
